Elevatus Welath Management Recursion Pharmaceuticals, Inc. Transaction History
Elevatus Welath Management
- $267 Billion
- Q2 2024
A detailed history of Elevatus Welath Management transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Elevatus Welath Management holds 342,567 shares of RXRX stock, worth $2.45 Million. This represents 0.96% of its overall portfolio holdings.
Number of Shares
342,567
Previous 29,650
1055.37%
Holding current value
$2.45 Million
Previous $296 Million
769.13%
% of portfolio
0.96%
Previous 0.12%
Shares
3 transactions
Others Institutions Holding RXRX
# of Institutions
285Shares Held
236MCall Options Held
972KPut Options Held
2.4M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl28.1MShares$202 Million1.92% of portfolio
-
Baillie Gifford & CO26.6MShares$190 Million0.16% of portfolio
-
Vanguard Group Inc Valley Forge, PA21.6MShares$154 Million0.0% of portfolio
-
Black Rock Inc. New York, NY17.3MShares$124 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA15.4MShares$110 Million1.74% of portfolio
About RECURSION PHARMACEUTICALS, INC.
- Ticker RXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 180,480,000
- Market Cap $1.29B
- Description
- Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...